Listen

Press releases

Receive e-mail alerts

Internal link ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
April 15, 2019 at 11:00 AM UTC
Internal link ProQR to Present at the H.C. Wainwright Global Life Sciences Conference
April 01, 2019 at 11:00 AM UTC
Internal link ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
March 26, 2019 at 08:01 PM UTC
Internal link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2
March 11, 2019 at 04:45 PM UTC
Internal link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
March 11, 2019 at 12:00 PM UTC
Internal link ProQR to Present at Cowen Health Care Conference
March 05, 2019 at 12:00 PM UTC
Internal link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
February 27, 2019 at 12:00 PM UTC
Internal link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
January 29, 2019 at 01:30 PM UTC
Internal link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
January 07, 2019 at 12:00 PM UTC
Internal link ProQR to Host R&D Day in New York on January 29
January 03, 2019 at 12:00 PM UTC
Internal link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
January 02, 2019 at 12:00 PM UTC
Internal link ProQR Announces Extraordinary General Meeting of Shareholders
December 27, 2017 at 12:00 PM UTC
Internal link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
November 29, 2017 at 12:00 PM UTC
Internal link ProQR to Present at the Annual Piper Jaffray Healthcare Conference
November 21, 2017 at 12:00 PM UTC
Internal link ProQR Announces Results for the Third Quarter of 2017
November 20, 2017 at 12:00 PM UTC
Internal link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares
November 14, 2017 at 12:44 PM UTC
Internal link ProQR Announces Proposed Public Offering of Ordinary Shares
November 13, 2017 at 09:01 PM UTC
Internal link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
November 13, 2017 at 12:00 PM UTC
Internal link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board
November 09, 2017 at 12:00 PM UTC
Internal link ProQR to Present at EuroTIDES Conference
October 31, 2017 at 11:00 AM UTC
Internal link ProQR Announces Management Change and Key Promotions
October 26, 2017 at 11:00 AM UTC
Internal link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
October 24, 2017 at 11:00 AM UTC
Internal link ProQR to Present at the Chardan Inaugural Gene Therapy Conference
October 06, 2017 at 11:00 AM UTC
Internal link ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
September 25, 2017 at 08:00 PM UTC
Internal link ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
September 21, 2017 at 11:05 AM UTC

Press releases

Internal link ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

Internal link ProQR to Present at the H.C. Wainwright Global Life Sciences Conference

Internal link ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership

Internal link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2

Internal link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

Internal link ProQR to Present at Cowen Health Care Conference

Internal link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

Internal link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day

Internal link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10

Internal link ProQR to Host R&D Day in New York on January 29

Internal link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2

Internal link ProQR Announces Extraordinary General Meeting of Shareholders

Internal link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

Internal link ProQR to Present at the Annual Piper Jaffray Healthcare Conference

Internal link ProQR Announces Results for the Third Quarter of 2017

Internal link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

Internal link ProQR Announces Proposed Public Offering of Ordinary Shares

Internal link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness

Internal link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board

Internal link ProQR to Present at EuroTIDES Conference

Internal link ProQR Announces Management Change and Key Promotions

Internal link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference

Internal link ProQR to Present at the Chardan Inaugural Gene Therapy Conference

Internal link ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis

Internal link ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology